Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Alnylam Pharmaceuticals (NQ: ALNY )

138.23 USD -4.27 (-3.00%)
Official Closing Price Updated: 5:20 PM EDT, Apr 9, 2021 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 419,900
Open 141.94
Bid (Size) 137.93 (23)
Ask (Size) 138.24 (18)
Prev. Close 142.50
Today's Range 137.10 - 142.31
52wk Range 114.30 - 178.41
Shares Outstanding 100,522,411
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Alnylam to Webcast Presentation at 20th Annual Needham Virtual Healthcare Conference
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present a company overview at the 20th Annual Needham Virtual Healthcare... 
From Business Wire News Releases
Alnylam Announces Publication of ILLUMINATE-A Phase 3 Study Results for Lumasiran in The New England Journal of Medicine
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that pivotal trial results from the ILLUMINATE-A Phase 3 study of lumasiran, an RNAi therapeutic... 
From Business Wire News Releases

Performance

YTD
+7.91%
+7.91%
1 Month
-3.32%
-3.32%
3 Month
-11.75%
-11.75%
6 Month
-5.97%
-5.97%
1 Year
+16.15%
+16.15%

More News

Read More
Alnylam to Webcast Presentation at Stifel 3rd Annual CNS Day
From Business Wire News Releases
Alnylam to Present Full 9-Month Results from the HELIOS-A Phase 3 Study of Vutrisiran at the American Academy of Neurology Virtual Annual Meeting 2021
From Business Wire News Releases
Alnylam Issues Inaugural Corporate Responsibility Summary
From Business Wire News Releases
Alnylam to Webcast Presentations at Upcoming March Investor Conferences
From Business Wire News Releases
Alnylam to Webcast Presentation at 10th Annual SVB Leerink Global Healthcare Conference
From Business Wire News Releases
Dicerna Sells Oxlumo Royalty Interest To Royalty Pharma For $180M Upfront
Tags Contracts Benzinga M&A
From Benzinga
Soleo Health to Administer Alnylam Pharmaceuticals’ GIVLAARI® (givosiran) for the Treatment of Acute Hepatic Porphyria in Adults
From Business Wire News Releases
Alnylam Pharmaceuticals Larger Than S&P 500 Component NetApp
Tags Stocks
From Market News Video
Alnylam's Oxalate-Lowering Therapy Shows Significant Clinical Benefit; Data Published In New England Journal Of Medicine
Tags ALNY Market News Biotech
From Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.